Cirmtuzumab
Cirmtuzumab
Cirmtuzumab (pronounced: sir-m-too-zoo-mab) is a novel monoclonal antibody designed to inhibit the ROR1 (Receptor tyrosine kinase-like Orphan Receptor 1) protein, a type of oncoprotein that is overexpressed in many different types of cancer.
Etymology
The name "Cirmtuzumab" is derived from the acronym CIRM (California Institute for Regenerative Medicine), which funded the initial research, and "tuzumab", a common suffix for monoclonal antibodies.
Mechanism of Action
Cirmtuzumab works by binding to the ROR1 protein on the surface of cancer cells. This binding inhibits the signaling pathways that promote cell survival and proliferation, thereby slowing or stopping the growth of the cancer.
Clinical Trials
Cirmtuzumab is currently being investigated in several clinical trials for its potential use in treating various types of cancer, including chronic lymphocytic leukemia (CLL), breast cancer, and lung cancer.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- ROR1: A protein that is overexpressed in many types of cancer and is the target of Cirmtuzumab.
- Oncoprotein: A protein that has the potential to cause cancer.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Clinical trial: A research study that tests how well new medical approaches work in people.
External links
- Medical encyclopedia article on Cirmtuzumab
- Wikipedia's article - Cirmtuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski